OPEN END TURBO CALL WARRANT - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000UK4QR17

Delayed Deutsche Boerse AG 06:56:52 26/06/2024 pm IST
1.8 EUR -1.64% Intraday chart for OPEN END TURBO CALL WARRANT - FRESENIUS MEDICAL CARE
Current month-15.67%
1 month-15.28%
Date Price Change
26/24/26 1.8 -1.64%
25/24/25 1.83 -2.66%
24/24/24 1.88 +5.03%
21/24/21 1.79 -5.79%
20/24/20 1.9 +1.60%

Delayed Quote Deutsche Boerse AG

Last update June 26, 2024 at 06:56 pm IST

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
Issuer UBS
WKN UK4QR1
ISINDE000UK4QR17
Date issued 30/08/2022
Strike 17.66
Maturity Unlimited
Parity 10 : 1
Emission price 1.74
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.25
Lowest since issue 0.92
Spread 0.01
Spread %0.55%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
35.67 EUR
Average target price
39.97 EUR
Spread / Average Target
+12.07%
Consensus